Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)
ICIs in the current study show survivals which are similar to those seen in seminal trials in patients with MSI-H mCRC. Low-dose ICIs appear to work in MSI-H mCRC and should be explored prospectively in clinical trials. Patients with MSI-H status should be exposed to ICIs, whether initially or later during treatment, whenever feasible.
Authors
- Aditya Dhanawat (ORCID: https://orcid.org/0000-0003-1910-5841)
- Abhishekram Raja
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- Omshree Shetty (ORCID: https://orcid.org/0000-0003-1996-4347)
- Avanish Saklani (ORCID: https://orcid.org/0000-0003-4498-7612)
- Anant Ramaswamy (ORCID: https://orcid.org/0000-0002-8169-4264)
- Vikas S Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- Subhash Yadav (ORCID: https://orcid.org/0000-0003-1116-6930)
- Munita Bal (ORCID: https://orcid.org/0000-0002-0345-5620)
- Sarika Mandavkar
- Himanshu Gujarathi
- Rajiv Kumar (ORCID: https://orcid.org/0000-0003-0363-3287)
- Noorzia Syed
- Laboni Sarkar
- Manan Vora
- Mehak Trikha
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/go.24.00141
- Citations
- 6
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.70